Previous 10 | Next 10 |
2024-02-15 17:01:35 ET More on Agile Therapeutics Seeking Alpha’s Quant Rating on Agile Therapeutics Historical earnings data for Agile Therapeutics Financial information for Agile Therapeutics Read the full article on Seeking Alpha For further...
Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Ye...
Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla ® for 49 Million Women These Actions Follow Several Months of Activity by the Biden Administration to Strengthen Access to All FDA Approved Contraceptives as Defined in ...
The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps New Report Follows Several Months of Activity by the Biden Administration and Lawmakers to Strengthen Access to Contraception as Defined in Pres...
2023-12-12 07:34:39 ET More on Agile Therapeutics Seeking Alpha’s Quant Rating on Agile Therapeutics Historical earnings data for Agile Therapeutics For further details see: Agile Therapeutics files to sell $15M of common stock, Series E-1 warrants
2023-12-04 13:30:59 ET Whether you subscribe to the idea that penny stocks are always a buy or determine your strategy based on broader market conditions, chances are that cheap stocks are on your watch list. While these sweeping market trends might not influence low-priced equities...
2023-11-22 09:26:16 ET More on Agile Therapeutics Agile Therapeutics, Inc. (AGRX) Q3 2023 Earnings Call Transcript Agile Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Agile Therapeutics Q3 2023 Earnings Preview Seeking Alpha’s Quant...
PRINCETON, NJ / ACCESSWIRE / November 22, 2023 / Agile Therapeutics, Inc. (NASDAQ:AGRX), the commercial-stage women's healthcare company, posted a 122% increase in third-quarter revenue year-over-year, driven by strong demand for TwirlaⓇ (levonorgestrel and ethinyl estradiol) transdermal ...
2023-11-09 13:14:03 ET Agile Therapeutics, Inc. (AGRX) Q3 2023 Earnings Call November 9, 2023 08:30 AM ET Company Participants Matt Riley - Head of Investor Relations Alfred Altomari - Chairman and Chief Executive Officer Scott Coiante - Chief Financial Officer ...
2023-11-09 08:12:42 ET More on Agile Therapeutics Agile Therapeutics Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Agile Therapeutics Historical earnings data for Agile Therapeutics Financial information for Agile Therapeutics For fu...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
NASDAQ Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 ...